Posted by Michael Wonder on 05 Jun 2024
Quince Therapeutics receives US FDA fast track designation for EryDex system
3 June 2024 - Quince Therapeutics today announced that the US FDA has granted fast track designation for its EryDex System for the treatment of patients with ataxia telangiectasia.
EryDex is comprised of dexamethasone sodium phosphate encapsulated in a patient’s own red blood cells utilising Quince’s proprietary autologous intracellular drug encapsulation technology platform.
